397 related articles for article (PubMed ID: 31321011)
1. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches.
Winer ES; Stone RM
Ther Adv Hematol; 2019; 10():2040620719860645. PubMed ID: 31321011
[TBL] [Abstract][Full Text] [Related]
2. Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development.
Stanchina M; Soong D; Zheng-Lin B; Watts JM; Taylor J
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33139625
[TBL] [Abstract][Full Text] [Related]
3. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
4. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Stahl M; Lu BY; Kim TK; Zeidan AM
Target Oncol; 2017 Aug; 12(4):413-447. PubMed ID: 28664386
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C; Ruella M; Paruzzo L; Tarella C; Pelicci PG; Colombo E
Blood Cancer Discov; 2024 Jul; 5(4):234-248. PubMed ID: 38904305
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
7. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials.
Sasine JP; Schiller GJ
Blood Rev; 2015 Jan; 29(1):1-9. PubMed ID: 25441922
[TBL] [Abstract][Full Text] [Related]
8. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
9. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
Assi R; Kantarjian H; Ravandi F; Daver N
Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy.
Rausch J; Ullrich E; Kühn MWM
Front Immunol; 2023; 14():1269012. PubMed ID: 37809078
[TBL] [Abstract][Full Text] [Related]
11. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
Mahalleh M; Shabani M; Rayzan E; Rezaei N
Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
[TBL] [Abstract][Full Text] [Related]
12. [Molecular targeted therapy for acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2023; 64(5):345-354. PubMed ID: 37271525
[TBL] [Abstract][Full Text] [Related]
13. [Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults].
Moritake H
Rinsho Ketsueki; 2020; 61(6):665-672. PubMed ID: 32624541
[TBL] [Abstract][Full Text] [Related]
14. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
15. Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia.
Böhme M; Kayser S
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008269
[TBL] [Abstract][Full Text] [Related]
16. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
17. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
[TBL] [Abstract][Full Text] [Related]
18. From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia.
Gurnari C; Voso MT; Maciejewski JP; Visconte V
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033196
[TBL] [Abstract][Full Text] [Related]
19. Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
Schorr C; Perna F
Front Immunol; 2022; 13():1085978. PubMed ID: 36605213
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
